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Introduction: Breast cancer a major health concern, especially in industrialized countries. 
Despite extensive research, a consensus does not yet exist regarding the association between 
breast cancer risk factors and its many outcomes. Because of the increasing rate of breast cancer 
in Iran, including in Yazd City, in this study we evaluated the relationship between survival and 
recurrence rates and patterns of risk factors in breast cancer patients. Methods: This analytical 
study was conducted retrospectively on 333 patients with breast cancer over an 8-year period 
(2005-2013). Total survival and recurrence rates were recorded in monthfor all patients; then the 
data were analyzed with the chi-square and log-rank tests and compared to other obtained data. 
Kaplan-Meier curves were used to analyze survival data. Results: The mean patient age was 
57.02 ± 12.32 years. The mean total survival rate was 93.15 ± 1.25 months (97.9%). The mean 
total recurrence rate was 84.59 ± 1.91 months (89.8%). Patients in all breast cancer subgroups 
had no significant relationship with risk factors (P>0.05), although body mass index (BMI) and 
recurrence rate were significantly related (P=0.045). Other risk factors were not significantly 
related to total survival and recurrence rates. The mean duration of oral contraceptive pill 
consumption was significantly longer in patients in the estrogen receptor-progesterone receptor-
HER2-positive subgroup than in other groups (P=0.03). Conclusion: We found that BMI lower 
than 25 kg/m2 was strong prognostic factor for recurrence in patients with triple-negative breast 
cancer. Because of the high survival rate of patients with breast cancer during our 8-year study 
period, we recommend that studies with larger sample sizes that are focused on survival period 
be conducted.
INTRODUCTION
Breast cancer has four main subgroups that are classified 
based on the expression of estrogen receptor-progesterone re-
ceptor (ER-PR) and HER2 genes (1). Currently, considering 
the increasing prevalence of breast cancer, it is important to 
evaluate treatment status and follow-up on patients from dif-
ferent subgroups (2). Recent reports have suggested that there 
is a significant relationship between recurrence rate and breast 
cancer subgroups in terms of response to treatment (3,4).
However, what is still unclear, and what shows the im-
portance of research in major cancer registry centers world-
wide, is the relationship between breast cancer subgroups 
and their diagnostic factors and risk factors (5). One group 
of researchers has suggested that breast cancer subgroups in 
different parts of the world vary in terms of outbreak, di-
agnostic patterns, surgical findings, response to treatment, 
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and ultimately survival rate (6). To understand and devise 
the correct treatment plan for patients, comprehensive infor-
mation should be available for all breast cancer subgroups 
in different societies. Therefore, we designed this study to 
evaluate the patterns of risk factors, survival rates, and re-
currence rates in patients with triple-negative breast cancer 
(TNBC) and other subtypes.
Our aim was to help improve the diagnosis and follow-up 
of patients and provide a basis for additional studies.
METHODS
This analytical study was conducted retrospectively on 333 
women with breast cancer who were referred to private med-
ical centers during an 8-year period (2005-2013). Patients 
were selected using the convenience sampling method, and 
all patients who were referred to the private Oncology Clin-
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ic and Hospital Shah Wali were included. All information 
was extracted from patient medical records and from direct 
contact with the patients. After collecting the necessary in-
formation and recording it in a questionnaire prepared for 
this purpose, the data were categorized based on breast can-
cer subtypes, including TNBC, triple-positive breast cancer 
(TPBC), and ER-PR-negative-HER2-positive breast cancer. 
Data were analyzed using SPSS software (SPSS Inc., Chi-
cago, IL, USA), and tables related to the required indica-
tors were prepared. Statistical analysis was performed using 
analysis of variance (ANOVA), the log-rank and chi-square 
tests, and the Kaplan-Meier survival curve. P values less 
than 0.05 were considered statistically significant.
RESULTS
The mean patient age was 57.02 ± 12.32 years; since P=0.76, 
no significant difference was observed between breast cancer 
subgroups and patient age. Patients were studied in terms of 
educational level, residence, and marital status. We found no 
significant relationship among educational level, residence, 
or marital status with breast cancer subgroups, as well as 
no significant relationship between rate of survival and re-
currence. Patients were evaluated for age (first pregnancy), 
number of pregnancies, history of breastfeeding, lactation 
duration (months), history of oral contraceptive pill (OCP) 
consumption, and duration of OCP consumption (months). 
No relationship was observed between the frequency distri-
bution of breast cancer subgroups and possible risk factors 
(P>0.05). The difference in duration of OCP consumption 
(months) was evaluated by ANOVA. Significant differences 
were observed between duration of OCP consumption in pa-
tients with breast cancer subgroups (P=0.03). In the subgroup 
of patients with ER-PR-HER2-positive breast cancer, the 
mean duration of OCP consumption was 22.22±15.03 years, 
which showed significant differences compared to other sub-
groups (Figure 1). However, no significant relationship was 
observed between duration of OCP consumption and breast 
cancer subgroups and the rates of survival and recurrence.
In our population, 2 patients were smokers and alco-
hol consumers; they were excluded from the study before 
the data were analyzed. The mean total survival rate was 
93.15 ± 1.25 months (97.9%). The mean survival rate of 
patients in the breast cancer subgroups was analyzed by 
the log-rank test, and no significant differences were ob-
served (P=0.33; Figure 2). The mean recurrence rate was 
84.59±1.91 months (89.8%). The mean recurrence rate after 
treatment in patients was analyzed in the breast cancer sub-
groups by the log-rank test, and no significant differences 
were observed (P=0.93; Figure 3). In the TNBC group, a 
significant relationship was observed between body mass in-
dex (BMI) and recurrence rate (P=0.045). Other risk factors 
had no significant relationship with the rate of survival and 
recurrence in the studied subgroups.
DISCUSSION
In our study, the mean total survival rate was 
93.15 ± 1.25 months (97.9%). This survival rate was related 
to an 8-year period, which is a longer period compared to 
other existing reports and studies in other countries. In a sim-
ilar study (2012) in France, the mean survival rate was re-
ported to be 78.2% over a 10-year period (7). Another study 
in Italy showed that the mean survival rate was 82.7% over 
a 5-year period (8). It appears that these findings, apart from 
Figure 1. Mean duration of oral contraceptive pill consumption 
in the studied population according to the breast cancer subgroups 
(TNBC: triple-negative breast cancer)
Figure 2. Mean survival rate in the studied population according 
to the breast cancer subgroups (TNBC: triple-negative breast 
cancer)
Figure 3. Mean recurrence rate after treatment (months) in the 
studied population according to the breast cancer subgroups
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the different time periods studied, also depend on other pre-
dictive factors, which are fundamentally the reason for the 
differences in various reports on the survival rate of patients 
with breast cancer (9, 10).
Age has always been a controversial factor in relation to 
survival rate. In our study, we found no significant correla-
tion between age and breast cancer subgroups. Dialla et al., 
according to reports from the National Cancer Registry Cen-
ter in Paris (7), suggested that age was an ineffective factor 
in predicting survival rates in breast cancer. However, this 
report was in contrast to a similar report from the Nether-
lands that was published in 2011 (11). Weggelaar et al. in-
troduced age as a strong predictor. They recommended that 
age be considered when devising patient treatment plans; 
furthermore, they suggested that age has a predictive role 
in response to treatment and can be effective in increasing 
survival (11).
Pregnancy and related factors can also affect survival 
rate; this has been discussed repeatedly in various studies. In 
our study, first gestational age was analyzed, and no signif-
icant relationship was observed between it and the survival 
and recurrence rates of the patients. Not even the frequency 
distribution of the first gestational age groups was signifi-
cant in the different subgroups. In this regard, some studies 
reported no relationship between pregnancy and prognosis 
and the survival rate of patients with breast cancer (12-16). 
Conversely, some reports were based on the relationship be-
tween the survival rate of patients and their pregnancy status 
and the first gestational age (17, 18); these studies suggest-
ed that pregnancy was effective at increasing the survival 
of breast cancer patients. Papatestas et al. (19) and Green 
et al. (20) suggested that history of pregnancy and childbirth 
was a negative factor in predicting the status of breast can-
cer; but, recently, many researchers have reported a direct 
relationship between age of last childbirth and the diagnosis 
of breast cancer with the survival rate of patients (21-23). 
Rosner and Lane reported that this was an inverse relation-
ship (24).
In our study, we also considered OCP consumption histo-
ry as a factor in breast cancer survival and recurrence rates, 
as well as mean duration of OCP consumption (months). 
We found no significant relationship in any case with sur-
vival of patients, which was consistent with the findings of 
other studies (12,24). Another study reported a significant 
relationship between OCP consumption and survival rate. 
The only significant finding in our study was that patients in 
the ER-PR-HER2-positive subgroup had a significantly lon-
ger history of OCP consumption; however, this relationship 
was not observed in any other study that we reviewed. Only 
Chlebowski et al. reported OCP consumption as a negative 
prognostic factor in prognosis and the survival rate of breast 
cancer. They observed a direct relationship between tumor 
size and long-term OCP consumption (25). However, several 
studies (26-29) suggested that OCP consumption was an ef-
fective factor in better prognosis of patients.
McDonald et al. (30) reported that alcohol consumption 
was a major factor in reducing the survival rate of breast can-
cer patients. In our study, no patient had a history of alcohol 
consumption, which is rooted in cultural beliefs and is reli-
ant upon patients’ reporting honestly. Some studies found no 
relationship between alcohol consumption and the survival 
rate of breast cancer patients (32, 31). Smoking history was 
reported in less than 1% of our population (2/333 patients); 
however, it was impossible to assess the association of smok-
ing with survival factors. Two studies found that smoking 
reduced the survival rate of breast cancer patients (33,34).
Finally, regarding the relationship in our study between 
BMI and survival and recurrence rates, patients in the TNBC 
subgroup with a BMI less than or equal to 25 kg/m2 had a 
significantly higher recurrence rate than patients with a BMI 
between 25 kg/m2 and 35 kg/m2 and more than 35 kg/m2. In 
terms of the possible mechanism of the role of BMI in sur-
vival, we can point to the relationship between obesity and 
plasma levels of hormones, including the growth hormone, 
especially when adipose tissue is the most important source 
of external estrogen in postmenopausal women. In addition, 
obesity is associated with a decrease in plasma levels of 
globulins bound to sex hormones (34,35). In other words, the 
incidence of hyperinsulinemia and hyperandrogenism is en-
hanced with increasing BMI in middle-aged women, while 
the current thinking is that estrogen levels do not change or 
they decrease only mildly. Insulin-like growth factor 1 and 
insulin are two important markers in explaining the mech-
anism for how the survival rate of breast cancer patients is 
reduced following an increase in BMI. Because this marker 
also stimulates cell proliferation, it also prevents apopto-
sis (36); in other words, while stimulating the production of 
sex steroids, it reduces the production of glucose bound to 
sex hormones (35).
Considering the increasing prevalence of breast cancer 
in Iran, especially in Yazd City, it is important to conduct 
similar studies and obtain more accurate results to develop 
experimental therapeutic programs for the design and imple-
mentation of a comprehensive breast cancer registry system. 
Even though we included all possible patients in our study, 
the sample size was still small and was a limitation. Con-
sidering the high survival rate of breast cancer patients, it 
is necessary to consider longer study periods or multicenter 
studies and provide access to more patients, so that more 
accurate and generalizable results can be obtained. Based on 
our findings, we suggest that accounting for the BMI of pa-
tients and the duration of their OCP consumption, especially 
in the TNBC subgroup, can be effective at predicting and 
setting treatment schedules.
CONCLUSION
In our study, the mean survival rate of breast cancer patients 
was higher than that reported in similar studies worldwide. 
However, no significant correlation was observed between 
total survival and recurrence rates of patients with possible 
risk factors, except for BMI in the TNBC subgroup. Because 
of the relatively small sample size, it was impossible to eval-
uate the relationship between risk factors and survival rate. 
Finally, a significant relationship was observed between the 
mean duration of OCP consumption and breast cancer in the 
ER-PR-HER2-positive subgroup. However, investigating 
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the mechanism of this phenomenon was beyond the scope 
of this study.
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